Case #1 Case #1 (cont) Case #1 (cont)

Slides:

Advertisements

Similar presentations

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with chronic systolic heart failure.

Advertisements

Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.

Discussant Inder Anand, MD, FRCP, D Phil (Oxon.)

CHARM Program: 3 Component trials comparing candesartan with placebo.

The INTENSIFY study: practical daily effectiveness and tolerance of ivabradine in chronic systolic heart failure in Germany Zugck C, Martinka P, Stöckl.

The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Heart rate reduction with ivabradine and health related quality of life in.

analysis from the SHIFT study

May 23rd, 2012 Hot topics from the Heart Failure Congress in Belgrade.

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Selective heart rate reduction with ivabradine unloads the left ventricle in.

Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure Systolic Heart.

ACCP Cardiology PRN Journal Club

Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.

CR-1 Candesartan in HF Benefit/Risk James B. Young, MD Cleveland Clinic Foundation.

New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.

Ivabradine – A new option for Heart Failure Patients

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

Valsartan in Acute Myocardial Infarction Trial Investigators

CLINICAL DILEMMAS IN HEART FAILURE:

Emerging Concepts in Heart Failure

Introduction: Alarming Statistics Causes of Death in Prevalent Dialysis Patients,

Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.

Diabetes and Dyslipidemia

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

Heart Rate, HF Admissions, and Readmissions

Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.

Cancer Stem Cell Therapies in Gastrointestinal Cancers

PCP Perspectives Clinical Considerations in Hyperkalemia

Managing Hereditary Angioedema

Patient Presentation Patient’s Changing Condition Multiple Considerations To Balance.

Cost Effectiveness and Optimal Outcomes in HF

Section III: Neurohormonal strategies in heart failure

Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

Treating HFrEF: Challenges Faced

PCSK9 Inhibitors and Cardiovascular Outcomes

Expert Insights on Complex Clinical Cases of Edema

Evaluating New Therapies in HF

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Mutational Testing to Select Novel Targeted Therapies in AML

Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?

The Importance of Getting the Dose Right in HF

Using Heart Rate as a Biomarker in Clinical Practice.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Updates in Heart Failure:

Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Shifting Currents in Hyperkalemia Management 2015 in Review

Shifting Currents in Hyperkalemia Management 2015 in Review

Challenging the Myths in Heart Failure With Reduced Ejection Fraction

CAD and HF Often Coexist

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Managing Pulmonary Embolism Posthospital Discharge

Section III: Neurohormonal strategies in heart failure

Maximizing Organ Protection in Patients With CKD and Comorbidities on RAAS Therapy.

DECLARE-TIMI 58.

Background. Current Perspectives on the Management of Iron Deficiency in Chronic Heart Failure.

2015 EASD In Review: CV Risk management in t2dm

Associations between β-blocker dosage group, predischarge heart rate group, and the primary composite outcome of death or cardiovascular rehospitalisation.

Real-World Evidence.

Uptitration of Medications in HF: Start Low but Aim High and Stay High

In-Hospital Treatment for Heart Failure: New Approaches and a Renewed Sense of Hope?

My PAH Patient.

Top Tips in Evidence-Based Care for HFrEF

Key Data on Improving Outcomes in HF Patients

Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure

Diagnosing HFpEF: What Every Cardiologist Needs to Know

Presentation transcript:

Case #1

Case #1 (cont)

Case #1 (cont)

Resting HR Matters

HR and β-Blocker Dose A Complex Issue

EVEREST Trial

Multiple HR Targets for Evaluation

MERIT-HF

Uptitration in Older Population

Ivabradine and If Channel

SHIFT Trial Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial

Effect of Ivabradine on Outcomes

SHIFT No Impact of β-Blocker Dose

Post hoc Analysis From the Phase 3 SHIFT Study

CHARM HR and Outcome in HF by Rhythm

Incidence of Selected Adverse Events (n = 19,083)

Highlighting Key Points

Abbreviations

References

References (cont)

References (cont)

References (cont)